Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Insmed Incorporated is a biopharmaceutical company focused on the development and commercialization of therapies for serious and rare diseases with high unmet medical need, particularly in the fields of pulmonary and inflammatory diseases. The company operates within the biotechnology and specialty pharmaceutical industries, generating revenue primarily from its marketed product while advancing a clinical-stage pipeline of novel therapeutics.
Insmed’s primary revenue driver is ARIKAYCE® (amikacin liposome inhalation suspension), an inhaled antibiotic approved for the treatment of refractory nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex. The company is strategically positioned as a specialist in complex pulmonary conditions, leveraging proprietary drug delivery technologies and deep clinical expertise. Founded in 1988, Insmed has evolved from an early-stage biotechnology company into a commercial-stage organization following the regulatory approval and global rollout of ARIKAYCE, while continuing to invest heavily in research and development.
Business Operations
Insmed operates primarily through a single integrated business model encompassing commercial operations and research and development. Revenue is generated mainly from sales of ARIKAYCE®, with commercial activities concentrated in the United States and select international markets. Research and development efforts are focused on advancing a pipeline of inhaled and biologic therapies targeting rare pulmonary and inflammatory diseases.
The company controls proprietary formulation and delivery technologies designed to optimize drug targeting in the lungs. Insmed conducts clinical development internally and utilizes third-party manufacturers and contract research organizations for production and trials. Key wholly owned subsidiaries support international operations, including Insmed Limited and Insmed Europe GmbH, which facilitate regulatory, commercial, and medical affairs activities outside the United States.
Strategic Position & Investments
Insmed’s strategic direction emphasizes pipeline expansion beyond ARIKAYCE and long-term value creation through innovation in rare disease therapeutics. The company is investing significantly in late-stage and mid-stage clinical programs, most notably brensocatib, an oral dipeptidyl peptidase 1 (DPP1) inhibitor being developed for non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases.
Strategic investments are primarily internal, focused on advancing clinical trials, scaling manufacturing capabilities, and expanding global commercial infrastructure. Insmed has also pursued selective acquisitions and licensing arrangements to strengthen its technology base, including the earlier acquisition of Transave, Inc., which provided the liposomal delivery platform underpinning ARIKAYCE. Emerging areas of focus include inflammatory lung diseases and other rare conditions where targeted delivery and disease-modifying approaches may provide competitive advantages.
Geographic Footprint
Insmed is headquartered in the United States, with its principal executive offices in Bridgewater, New Jersey. The company has a strong commercial presence in North America, which represents its largest revenue-generating region, supported by a dedicated sales and medical affairs organization.
Internationally, Insmed has expanded its footprint across Europe and parts of Asia-Pacific, where ARIKAYCE has received regulatory approvals or is undergoing commercialization. Through its subsidiaries and partnerships, the company maintains operational and regulatory influence across multiple continents, supporting clinical trials, market access initiatives, and post-marketing surveillance in global markets.
Leadership & Governance
Insmed is led by an experienced executive team with deep expertise in biotechnology, rare diseases, and global pharmaceutical commercialization. The leadership philosophy emphasizes patient-centric innovation, disciplined capital allocation, and long-term scientific investment to address underserved medical needs.
Key executives include:
- William Lewis – President and Chief Executive Officer
- Jeffrey A. Huber – Executive Vice President and Chief Financial Officer
- Michael C. Smith – Chief Legal Officer and Corporate Secretary
- Michael E. Dastoor – Chief Commercial Officer
- Martina M. Fluck – Chief Medical Officer
The company is governed by an independent board of directors that provides oversight on strategy, risk management, and corporate governance, consistent with U.S. public company and SEC reporting standards.